Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 13/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 13/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | KLK7 | P49862 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20486302 | 0.85 | MEN1 (0.60) | MEN1KMT2APOLBKLK7MAPT | |
| SCHEMBL20487324 | 0.84 | MEN1 (0.57) | MEN1KMT2APOLBKLK7MAPT | |
| SCHEMBL20487577 | 0.81 | MEN1 (0.84) | MEN1KMT2APOLBKLK7MAPT | |
| SCHEMBL22022050 | 0.81 | MEN1 (0.50) | MEN1KMT2APOLBKLK7MAPT | |
| SCHEMBL20487327 | 0.81 | MEN1 (0.53) | MEN1KMT2APOLBKLK7MAPT | |
| SCHEMBL20486435 | 0.79 | MAPT (0.60) | MEN1KMT2APOLBMAPT | |
| SCHEMBL20486544 | 0.79 | MEN1 (0.48) | MEN1KMT2APOLBKLK7MAPT | |
| SCHEMBL20486316 | 0.79 | MEN1 (0.48) | MEN1KMT2APOLBKLK7MAPT | |
| SCHEMBL20487475 | 0.79 | MEN1 (0.48) | MEN1KMT2APOLBKLK7MAPT | |
| SCHEMBL20487549 | 0.79 | MEN1 (0.47) | MEN1KMT2APOLBKLK7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230075856-A1 | CYCLIC SULFAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES INC (US) | 2023-03-09 | — | — | US | disclosed |
| US-20230012463-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230012463-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2023-01-12 | — | — | US | disclosed |
| US-20220081433-A1 | CYCLIC SULFAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES INC (US) | 2022-03-17 | — | — | US | disclosed |
| US-11078170-B2 | Cyclic sulfamide compounds and methods of using same | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11078170-B2 | Cyclic sulfamide compounds and methods of using same | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| CN-113164493-A | Cyclic sulfonamide compounds for the treatment of HBV | 组装生物科学股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113166086-A | Cyclic sulfonamide compounds for the treatment of HBV | 组装生物科学股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3846820-A1 | CYCLIC SULFAMIDE COMPOUNDS FOR TREATMENT OF HBV | Assembly Biosciences, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3589630-B1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3589630-B1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2021-07-07 | — | — | EP | disclosed |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2020-05-21 | — | — | US | disclosed |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2020-05-21 | — | — | US | disclosed |
| CN-110621672-A | Cyclic sulfonamide compounds and methods of use thereof | 组装生物科学股份有限公司 | 2019-12-27 | — | — | CN | disclosed |
| WO-2018160878-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES, INC. (US) | 2018-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230075856-A1 | CYCLIC SULFAMIDE COMPOUNDS FOR TREATMENT OF HBV | HCCS, HAVCR2, SMC1A | MEN1 4367/4885KMT2A 2920/4885POLB 597/4885 |
| US-20230012463-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | HCCS, HAVCR2, SLC10A1 | MEN1 3885/4885KMT2A 2749/4885POLB 642/4885 |
| US-20220081433-A1 | CYCLIC SULFAMIDE COMPOUNDS FOR TREATMENT OF HBV | HCCS, HAVCR2, SMC1A | MEN1 4367/4885KMT2A 2920/4885POLB 597/4885 |
| US-11078170-B2 | Cyclic sulfamide compounds and methods of using same | HCCS, HAVCR2, SLC10A1 | MEN1 3885/4885KMT2A 2749/4885POLB 642/4885 |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | HCCS, HAVCR2, SLC10A1 | MEN1 3885/4885KMT2A 2749/4885POLB 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.